343 related articles for article (PubMed ID: 32699136)
1. P2X7 Receptor Activity Limits Accumulation of T Cells within Tumors.
Romagnani A; Rottoli E; Mazza EMC; Rezzonico-Jost T; De Ponte Conti B; Proietti M; Perotti M; Civanelli E; Perruzza L; Catapano AL; Baragetti A; Tenedini E; Tagliafico E; Falzoni S; Di Virgilio F; Norata GD; Bicciato S; Grassi F
Cancer Res; 2020 Sep; 80(18):3906-3919. PubMed ID: 32699136
[TBL] [Abstract][Full Text] [Related]
2. The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment.
De Marchi E; Orioli E; Pegoraro A; Sangaletti S; Portararo P; Curti A; Colombo MP; Di Virgilio F; Adinolfi E
Oncogene; 2019 May; 38(19):3636-3650. PubMed ID: 30655604
[TBL] [Abstract][Full Text] [Related]
3. P2RX7 Enhances Tumor Control by CD8+ T Cells in Adoptive Cell Therapy.
Wanhainen KM; Peng C; Zhou MH; Macedo BG; O'Flanagan S; Yang T; Kelekar A; Burbach BJ; Borges da Silva H; Jameson SC
Cancer Immunol Res; 2022 Jul; 10(7):871-884. PubMed ID: 35588154
[TBL] [Abstract][Full Text] [Related]
4. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
[TBL] [Abstract][Full Text] [Related]
5. Sialic Acid Blockade Suppresses Tumor Growth by Enhancing T-cell-Mediated Tumor Immunity.
Büll C; Boltje TJ; Balneger N; Weischer SM; Wassink M; van Gemst JJ; Bloemendal VR; Boon L; van der Vlag J; Heise T; den Brok MH; Adema GJ
Cancer Res; 2018 Jul; 78(13):3574-3588. PubMed ID: 29703719
[TBL] [Abstract][Full Text] [Related]
6. Feasibility study of B16 melanoma therapy using oxidized ATP to target purinergic receptor P2X7.
Hattori F; Ohshima Y; Seki S; Tsukimoto M; Sato M; Takenouchi T; Suzuki A; Takai E; Kitani H; Harada H; Kojima S
Eur J Pharmacol; 2012 Nov; 695(1-3):20-6. PubMed ID: 22981895
[TBL] [Abstract][Full Text] [Related]
7. CD39 limits P2X7 receptor inflammatory signaling and attenuates sepsis-induced liver injury.
Savio LEB; de Andrade Mello P; Figliuolo VR; de Avelar Almeida TF; Santana PT; Oliveira SDS; Silva CLM; Feldbrügge L; Csizmadia E; Minshall RD; Longhi MS; Wu Y; Robson SC; Coutinho-Silva R
J Hepatol; 2017 Oct; 67(4):716-726. PubMed ID: 28554875
[TBL] [Abstract][Full Text] [Related]
8. CD8
Mellouk A; Bobé P
FASEB J; 2019 Mar; 33(3):3225-3236. PubMed ID: 30383448
[TBL] [Abstract][Full Text] [Related]
9. Targeting
Le PT; Ha N; Tran NK; Newman AG; Esselen KM; Dalrymple JL; Schmelz EM; Bhandoola A; Xue HH; Singh PB; Thai TH
Front Immunol; 2021; 12():738958. PubMed ID: 34721405
[TBL] [Abstract][Full Text] [Related]
10. Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate.
Feng L; Sun X; Csizmadia E; Han L; Bian S; Murakami T; Wang X; Robson SC; Wu Y
Neoplasia; 2011 Mar; 13(3):206-16. PubMed ID: 21390184
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial arginase-2 is a cell‑autonomous regulator of CD8+ T cell function and antitumor efficacy.
Martí i Líndez AA; Dunand-Sauthier I; Conti M; Gobet F; Núñez N; Hannich JT; Riezman H; Geiger R; Piersigilli A; Hahn K; Lemeille S; Becher B; De Smedt T; Hugues S; Reith W
JCI Insight; 2019 Nov; 4(24):. PubMed ID: 31751318
[TBL] [Abstract][Full Text] [Related]
13. ATP-P2X7-Induced Inflammasome Activation Contributes to Melanocyte Death and CD8
Ahn Y; Seo J; Lee EJ; Kim JY; Park MY; Hwang S; Almurayshid A; Lim BJ; Yu JW; Oh SH
J Invest Dermatol; 2020 Sep; 140(9):1794-1804.e4. PubMed ID: 32035094
[TBL] [Abstract][Full Text] [Related]
14. Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response.
Zhang X; Niedermann G
Int J Radiat Oncol Biol Phys; 2018 May; 101(1):63-73. PubMed ID: 29534901
[TBL] [Abstract][Full Text] [Related]
15. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
16. The purinergic receptor P2RX7 directs metabolic fitness of long-lived memory CD8
Borges da Silva H; Beura LK; Wang H; Hanse EA; Gore R; Scott MC; Walsh DA; Block KE; Fonseca R; Yan Y; Hippen KL; Blazar BR; Masopust D; Kelekar A; Vulchanova L; Hogquist KA; Jameson SC
Nature; 2018 Jul; 559(7713):264-268. PubMed ID: 29973721
[TBL] [Abstract][Full Text] [Related]
17. Improving function of cytotoxic T-lymphocytes by transforming growth factor-β inhibitor in oral squamous cell carcinoma.
Kondo Y; Suzuki S; Takahara T; Ono S; Goto M; Miyabe S; Sugita Y; Ogawa T; Ito H; Satou A; Tsuzuki T; Yoshikawa K; Ueda R; Nagao T
Cancer Sci; 2021 Oct; 112(10):4037-4049. PubMed ID: 34309966
[TBL] [Abstract][Full Text] [Related]
18. Inactivation of Proprotein Convertases in T Cells Inhibits PD-1 Expression and Creates a Favorable Immune Microenvironment in Colorectal Cancer.
Tomé M; Pappalardo A; Soulet F; López JJ; Olaizola J; Leger Y; Dubreuil M; Mouchard A; Fessart D; Delom F; Pitard V; Bechade D; Fonck M; Rosado JA; Ghiringhelli F; Déchanet-Merville J; Soubeyran I; Siegfried G; Evrard S; Khatib AM
Cancer Res; 2019 Oct; 79(19):5008-5021. PubMed ID: 31358531
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of SHP-1 Expands the Repertoire of Antitumor T Cells Available to Respond to Immune Checkpoint Blockade.
Snook JP; Soedel AJ; Ekiz HA; O'Connell RM; Williams MA
Cancer Immunol Res; 2020 Apr; 8(4):506-517. PubMed ID: 32075800
[TBL] [Abstract][Full Text] [Related]
20. Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.
Weigelin B; Bolaños E; Teijeira A; Martinez-Forero I; Labiano S; Azpilikueta A; Morales-Kastresana A; Quetglas JI; Wagena E; Sánchez-Paulete AR; Chen L; Friedl P; Melero I
Proc Natl Acad Sci U S A; 2015 Jun; 112(24):7551-6. PubMed ID: 26034288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
